In a report issued on September 10, Andrew Semple from Echelon Wealth Partners maintained a Buy rating on Columbia Care (CCHWF), with a price target of C$9.50. The company’s shares closed last Monday at $3.85.
According to TipRanks.com, Semple is a 5-star analyst with an average return of 50.2% and a 82.6% success rate. Semple covers the Basic Materials sector, focusing on stocks such as Green Thumb Industries, Fire & Flower Holdings, and Trulieve Cannabis.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Columbia Care with a $7.47 average price target, representing a 101.9% upside. In a report issued on September 1, Beacon also reiterated a Buy rating on the stock with a C$7.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.30 and a one-year low of $0.78. Currently, Columbia Care has an average volume of 91.61K.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CCHWF in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Columbia Care, Inc. engages in the cultivation, manufacture and provision of medical cannabis products and services. It distributes its products under the EleCeed, TheraCeed, and ClaraCeed brands. The company was founded by Nicholas Vita and Michael Abbott in 2012 and is headquartered in New York, NY.
Read More on CCHWF:
